UroGen Pharma Ltd. (URGN)
NASDAQ: URGN · Real-Time Price · USD
10.08
-0.63 (-5.88%)
At close: Feb 21, 2025, 4:00 PM
10.27
+0.19 (1.86%)
After-hours: Feb 21, 2025, 5:54 PM EST
UroGen Pharma Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for UroGen Pharma stock have an average target of 42.25, with a low estimate of 25 and a high estimate of 64. The average target predicts an increase of 319.15% from the current stock price of 10.08.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for UroGen Pharma stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 4 | 4 | 4 | 4 | 5 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 5 | 5 | 5 | 5 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $25 | Strong Buy | Maintains | $25 | +148.02% | Feb 20, 2025 |
| Ladenburg Thalmann | Ladenburg Thalmann | Strong Buy Initiates $31 | Strong Buy | Initiates | $31 | +207.54% | Feb 19, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $25 | Strong Buy | Maintains | $25 | +148.02% | Feb 18, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $25 | Strong Buy | Maintains | $25 | +148.02% | Feb 12, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $25 | Strong Buy | Maintains | $25 | +148.02% | Jan 23, 2025 |
Financial Forecast
Revenue This Year
92.78M
from 82.71M
Increased by 12.17%
Revenue Next Year
133.81M
from 92.78M
Increased by 44.23%
EPS This Year
-3.22
from -3.55
EPS Next Year
-2.86
from -3.22
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 98.1M | 159.7M | 411.1M | |||
| Avg | 92.8M | 133.8M | 280.6M | |||
| Low | 82.9M | 111.9M | 215.3M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 18.6% | 72.1% | 207.2% | |||
| Avg | 12.2% | 44.2% | 109.7% | |||
| Low | 0.3% | 20.6% | 60.9% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -3.10 | -1.29 | 2.34 | |||
| Avg | -3.22 | -2.86 | -0.43 | |||
| Low | -3.26 | -4.32 | -1.65 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.